<DOC>
	<DOCNO>NCT00675103</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical effect re-exposure 24 week course treatment pegloticase i.v . subject whose last exposure pegloticase i.v . least one year study entry . This study limit four study center US .</brief_summary>
	<brief_title>Re-exposure Study Pegloticase Intravenous ( i.v . ) Symptomatic Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Previous treatment study pegloticase i.v . Last exposure pegloticase i.v . great one year prior study entry Symptomatic gout Documented hyperuricemic ( SUA ≥ 7 mg/dL ) Prior exposure Elitek® ( rasburicase ) Unstable angina Uncontrolled arrhythmia hypertension Noncompensated congestive heart failure End stage renal disease require dialysis Concomitant use SUA lower agent use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Gout</keyword>
	<keyword>Gouty Arthritis</keyword>
	<keyword>Anti-Gout preparation</keyword>
</DOC>